The dyslipidemia drugs market is experiencing steady growth as the global burden of cardiovascular diseases continues to rise. Dyslipidemia, characterized by abnormal cholesterol and lipid levels, is one of the leading risk factors for heart disease and stroke. Increasing awareness of preventive healthcare, improvements in lipid-lowering therapies, and growing emphasis on early disease...